Pharmacokinetics of antiepileptic drugs
- PMID:9818917
- DOI: 10.1212/wnl.51.5_suppl_4.s2
Pharmacokinetics of antiepileptic drugs
Abstract
Enzymatic biotransformation is the principal determinant of the pharmacokinetic properties of most antiepileptic drugs (AEDs), although some agents are excreted by the kidneys predominantly as unchanged drug. Most AEDs exhibit linear enzyme kinetics, in which changes in daily dose lead to proportional changes in serum concentration if clearance remains constant. There are several important applications of pharmacokinetics in clinical practice. Established therapeutic ranges help guide drug administration to achieve serum concentrations that control seizures without causing intolerable toxicity. Determination of the elimination half-life may provide a basis for selecting a dosing interval and predicting the time to steady-state concentration. However, the traditional concept of administering a drug at intervals equal to one elimination half-life does not apply to some drugs. With vigabatrin, the half-life of biologic activity greatly exceeds the half-life of elimination. In situations in which it is desirable to achieve a steady-state serum concentration immediately, a loading dose can be calculated from a drug's volume of distribution and its desired serum concentration. Many AEDs have the potential to be involved in pharmacokinetic drug interactions when they are co-administered with other AEDs or other medications. These interactions usually involve changes in the rate of biotransformation or in the protein binding of one or both co-administered drugs.
Similar articles
- Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.Perucca E, Cloyd J, Critchley D, Fuseau E.Perucca E, et al.Epilepsia. 2008 Jul;49(7):1123-41. doi: 10.1111/j.1528-1167.2008.01665.x.Epilepsia. 2008.PMID:18503564
- Pharmacokinetic properties of current antiepileptic drugs: what improvements are needed?Bourgeois BF.Bourgeois BF.Neurology. 2000;55(11 Suppl 3):S11-6.Neurology. 2000.PMID:11147563Review.
- Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?Johannessen SI, Tomson T.Johannessen SI, et al.Clin Pharmacokinet. 2006;45(11):1061-75. doi: 10.2165/00003088-200645110-00002.Clin Pharmacokinet. 2006.PMID:17048972Review.
- The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come?Perucca E, Johannessen SI.Perucca E, et al.Epileptic Disord. 2003 May;5 Suppl 1:S17-26.Epileptic Disord. 2003.PMID:12915337Review.
- Antiepileptic drug interactions.French JA, Gidal BE.French JA, et al.Epilepsia. 2000;41 Suppl 8:S30-6. doi: 10.1111/j.1528-1157.2000.tb02944.x.Epilepsia. 2000.PMID:11092610Review.
Cited by
- Pharmacogenomic association study on the role of drug metabolizing, drug transporters and drug target gene polymorphisms in drug-resistant epilepsy in a north Indian population.Kumari R, Lakhan R, Garg RK, Kalita J, Misra UK, Mittal B.Kumari R, et al.Indian J Hum Genet. 2011 May;17 Suppl 1(Suppl 1):S32-40. doi: 10.4103/0971-6866.80357.Indian J Hum Genet. 2011.PMID:21747585Free PMC article.
- Epilepsy in brain metastasis: an emerging entity.Rudà R, Mo F, Pellerino A.Rudà R, et al.Curr Treat Options Neurol. 2020 Feb 8;22(2):6. doi: 10.1007/s11940-020-0613-y.Curr Treat Options Neurol. 2020.PMID:32034533Review.
- Modulation of the GABAergic pathway for the treatment of fragile X syndrome.Lozano R, Hare EB, Hagerman RJ.Lozano R, et al.Neuropsychiatr Dis Treat. 2014 Sep 16;10:1769-79. doi: 10.2147/NDT.S42919. eCollection 2014.Neuropsychiatr Dis Treat. 2014.PMID:25258535Free PMC article.Review.
- Choice of antiepileptic drugs affects the outcome in cancer patients with seizures.Cacho-Diaz B, San-Juan D, Salmeron K, Boyzo C, Lorenzana-Mendoza N.Cacho-Diaz B, et al.Clin Transl Oncol. 2018 Dec;20(12):1571-1576. doi: 10.1007/s12094-018-1892-6. Epub 2018 Jun 4.Clin Transl Oncol. 2018.PMID:29869040
- Genetic polymorphism of NAT2 metabolizing enzymes on phenytoin pharmacokinetics in Indian epileptic patients developing toxicity.Murali M, Manjari T, Madhuri B, Raghavan S, Jain DC, Vivekanandhan S.Murali M, et al.CNS Neurosci Ther. 2012 Apr;18(4):350-8. doi: 10.1111/j.1755-5949.2011.00291.x. Epub 2012 Jan 24.CNS Neurosci Ther. 2012.PMID:22268821Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources